Developing thalidomide analogues for cancer treatment

In summary

Professor Dalgleish collaborated with Celgene to develop safer and more effective thalidomide analogues that modulate the immune system and inhibit tumor growth.

These drugs have been approved in the UK and US and have greatly improved survival rates for myeloma and related blood cancers, while also driving growth in cancer therapeutics research.

What did we explore and how?

Initially observing thalidomide’s immune-modulatory effects in HIV patients, Professor Dalgleish identified the need for safer analogues due to thalidomide’s serious side effects.

Partnering with Celgene, the team developed and patented several analogues, focusing on lenalidomide and pomalidomide.

Clinical trials confirmed these drugs’ immune-stimulatory, anti-inflammatory, and anti-angiogenic properties.

Pre-clinical studies also demonstrated enhanced vaccine responses. These findings supported further clinical development and combination therapy trials for blood cancers.

Benefits and influence of this research

The introduction of lenalidomide and pomalidomide has significantly improved survival rates for multiple myeloma patients, increasing five-year survival from 20% to 37%.

These drugs have also been extended to treat other blood cancers, such as chronic leukemias and lymphomas.

Their success fueled the growth of Celgene from a small company to a global pharmaceutical leader, funding further UK research and clinical trials.

In 2012, lenalidomide generated $3.8 billion USD in sales, underscoring its global impact on cancer treatment.